Recruiting
Phase 3

Sacituzumab Tirumotecan & Pembrolizumab

Sponsor:

Merck Sharp & Dohme LLC

Code:

NCT06393374

Conditions

Triple-Negative Breast Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Pembrolizumab

Sacituzumab tirumotecan

Capecitabine

Study Details

Brief summary:

This is a randomized, open-label study comparing the efficacy and safety of adjuvant sacituzumab tirumotecan (MK-2870) in combination with pembrolizumab compared to treatment of physician's choice (TPC) in participants with triple-negative breast cancer (TNBC) who received neoadjuvant therapy and did not achieve a pathological complete response (pCR) at surgery. The primary objective is to compare sacituzumab tirumotecan plus pembrolizumab to TPC (pembrolizumab or pembrolizumab plus capecitabine) with respect to invasive disease-free survival (iDFS) per investigator assessment. It is hypothesized that sacituzumab tirumotecan plus pembrolizumab is superior to TPC with respect to iDFS per investigator assessment.

Conditions

Triple-Negative Breast Cancer

Study ID

NCT06393374

Start date

Jun 24, 2024

Status verified date

Sep, 2026

Completion date

Dec 14, 2037

Anticipated

Primary completion date

Dec 16, 2030

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Has centrally confirmed TNBC, as defined by the most recent American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines
  • Has no evidence of locoregional or distant relapse, as assessed by the treating physician
  • Had neoadjuvant treatment based on the KEYNOTE-522 regimen (pembrolizumab with carboplatin/taxanes and pembrolizumab with anthracycline-based chemotherapy) followed by surgery according to National Comprehensive Cancer Network (NCCN) treatment guidelines for TNBC
  • Had adequate excision and surgical removal of all clinically evident disease in the breast and/or lymph nodes and have adequately recovered from surgery
  • Has non-pathologic complete response at surgery
  • Is able to continue on adjuvant pembrolizumab
  • Randomization must be conducted within 16 weeks from surgical resection
  • Completed adjuvant radiation therapy (if indicated) and recovered before randomization
  • Has provided tissue from the surgical resection for central laboratory determination of trophoblast cell surface antigen 2 (TROP2) status
  • If capable of producing sperm, the participant agrees to the following during the intervention period and for at least the time needed to eliminate each study intervention after the last dose of study intervention (120 days for sacituzumab tirumotecan and 95 days for capecitabine \[no restriction for pembrolizumab\]): agrees to refrain from donating sperm AND is either abstinent and agrees to remain abstinent or uses highly effective contraception
  • For females (assigned at birth), is not pregnant or breastfeeding and ≥1 of the following applies: is not a participant of childbearing potential (POCBP) OR is a POCBP and uses highly effective contraception after the last dose of study intervention (210 days for sacituzumab tirumotecan, 120 days for pembrolizumab, and 185 days for capecitabine). Abstains from breastfeeding during the study intervention period and for at least 120 days after study intervention
  • Participants who have AEs due to previous anticancer therapies must have recovered to ≤Grade 1 or baseline (except alopecia)
  • Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on antiretroviral therapy (ART)
  • An Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 assessed within 7 days before first dose of study treatment
  • Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received hepatitis B birus (HBV) antiviral therapy for at least 4 weeks, and have undetectable HBV viral load prior to randomization

Exclusion Criteria:

  • Has a known germline breast cancer gene (BRCA) mutation (deleterious or suspected deleterious) and is eligible for adjuvant therapy with olaparib where olaparib is approved and available
  • Has Grade >2 peripheral neuropathy
  • History of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or severe corneal disease that prevents/delays corneal healing
  • Has active inflammatory bowel disease requiring immunosuppressive medication or previous history of inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis, or chronic diarrhea)
  • Has uncontrolled, significant cardiovascular disease or cerebrovascular disease including New York Heart Association Class III or IV congestive heart failure, unstable angina, myocardial infarction, uncontrolled symptomatic arrhythmia, prolongation of QTcF interval to >480 ms, and/or other serious cardiovascular and cerebrovascular diseases within 6 months prior to study intervention
  • Received prior treatment with a trophoblast cell-surface antigen 2 (TROP2)-directed antibody drug conjugate (ADC) or a topoisomerase I inhibitor-containing ADC
  • Received anticancer therapy in the adjuvant phase including but not limited to chemotherapy, small molecule anticancer drugs, poly (adenosine diphosphate ribose) polymerase (PARP) inhibitors, ADCs, and/or immunotherapy, with the exception of adjuvant radiation therapy
  • Is currently receiving a strong inducer/inhibitor of cytochrome P450 3A4 (CYP3A4) that cannot be discontinued for the duration of the study. The required washout period before starting sacituzumab tirumotecan is 2 weeks
  • Except for pembrolizumab as neoadjuvant therapy for early-stage TNBC: received prior therapy with an anti-programmed cell death 1 protein (anti-PD-1), anti-programmed cell death ligand 1 (anti-PD-L1), or anti-PD-L2 agent, or with an agent directed to another stimulatory or coinhibitory T-cell receptor (eg, cytotoxic T-lymphocyte-associated protein-4 \[CTLA-4\], OX-40 \[cluster of differentiation (CD) 134\], or CD137)
  • Except for chemotherapy as neoadjuvant therapy for early-stage TNBC: Received prior systemic anticancer therapy including investigational agents within 4 weeks before randomization
  • Received prior radiotherapy within 3 weeks of start of study intervention or required corticosteroids for radiation related toxicities that cannot be discontinued before the first dose of study intervention
  • Received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines are allowed
  • Has received an investigational agent or has used an investigational device within 4 weeks prior to study intervention administration
  • Has known additional malignancy that is progressing or has required active treatment within the past 5 years
  • Has diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of study medication
  • Has active autoimmune disease that has required systemic treatment in the past 2 years. Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid) is allowed
  • Has history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease
  • Has active infection requiring systemic therapy
  • HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
  • Has concurrent active hepatitis B and hepatitis C virus infection
  • Has history of allogeneic tissue/solid organ transplant

Study Design

Enrollment

1530 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Pembrolizumab + sacituzumab tirumotecan

Participants receive pembrolizumab every 6 weeks (q6w) in combination with sacituzumab tirumotecan every 2 weeks (q2w) for 24 weeks. In addition, participants receive an antihistamine, an H2 antagonist of investigator's choice, acetaminophen (or equivalent), and dexamethasone (or equivalent) per each drug's product label prior to sacituzumab tirumotecan infusions.

active comparator: Treatment of Physician's Choice

Participants receive pembrolizumab q6w or pembrolizumab q6w in combination with capecitabine (twice daily \[BID\] on Days 1 to 14 and 22 to 35 every 42 days x 4 \[2 weeks 1, 1 week off\]) for 24 weeks.

Interventions

Pembrolizumab

Pembrolizumab 400 mg intravenous (IV) infusion q6w

Sacituzumab tirumotecan

Sacituzumab tirumotecan 4 mg/kg IV infusion q2w

Capecitabine

Capecitabine 1000 mg/m\^2 to 1250 mg/m\^2 by mouth BID

Primary outcome measure

  • Invasive Disease-Free Survival (iDFS) [ Time Frame: Up to ~77 months ]

Central Contacts and Locations

Central contacts

Toll Free Number

1-888-577-8839Trialsites@msd.com

Locations

Infirmary Cancer Care ( Site 0001)

Recruiting

Mobile, Alabama, United States, 36607

Contacts

Study Coordinator

251-435-2273

Ironwood Cancer & Research Centers-Research ( Site 0054)

Recruiting

Chandler, Arizona, United States, 85224

Contacts

Study Coordinator

480-821-2838

MemorialCare Orange Coast Medical Center ( Site 9501)

Recruiting

Fountain Valley, California, United States, 92708

Contacts

Study Coordinator

714-378-7000

Scripps Cancer Center ( Site 0052)

Recruiting

La Jolla, California, United States, 92037

Contacts

Study Coordinator

800-727-4777

Kaiser Permanente - Oakland ( Site 0079)

Recruiting

Oakland, California, United States, 94611

Contacts

Study Coordinator

877-642-4691

Profound Research LLC ( Site 0105)

Recruiting

Oceanside, California, United States, 92056

Contacts

Study Coordinator

760-826-2020

Kaiser Permanente - Roseville ( Site 0081)

Recruiting

Roseville, California, United States, 95661

Contacts

Study Coordinator

877-642-4691

Kaiser Permanente - San Francisco ( Site 0080)

Recruiting

San Francisco, California, United States, 94115

Contacts

Study Coordinator

877-642-4691

Kaiser Permanente - Santa Clara ( Site 0082)

Recruiting

Santa Clara, California, United States, 95051

Contacts

Study Coordinator

877-642-4691

Providence Medical Foundation ( Site 9543)

Recruiting

Santa Rosa, California, United States, 95403

Contacts

Study Coordinator

707-528-1050

Kaiser Permanente Vallejo Medical Center ( Site 0060)

Recruiting

Vallejo, California, United States, 94589

Contacts

Study Coordinator

877-642-4691

Kaiser Permanente - Walnut Creek ( Site 0078)

Recruiting

Walnut Creek, California, United States, 94596

Contacts

Study Coordinator

877-642-4691

Cancer Centers of Colorado St. Mary's Regional Hospital ( Site 0046)

Recruiting

Grand Junction, Colorado, United States, 81501

Contacts

Study Coordinator

970-298-7500

University of Connecticut Health Center ( Site 0128)

Recruiting

Farmington, Connecticut, United States, 06030

Contacts

Study Coordinator

860-679-2100

Yale Cancer Center ( Site 0053)

Recruiting

New Haven, Connecticut, United States, 06510

Contacts

Study Coordinator

203-688-4242

Helen F. Graham Cancer Center & Research Institute ( Site 0018)

Recruiting

Newark, Delaware, United States, 19713

Contacts

Study Coordinator

302-366-1200

AdventHealth Altamonte Springs ( Site 0125)

Recruiting

Altamonte Springs, Florida, United States, 32701

Contacts

Study Coordinator

407-834-5151

Orlando Health Cancer Institute ( Site 0030)

Recruiting

Orlando, Florida, United States, 32806

Contacts

Study Coordinator

321-843-8370

Comprehensive Hematology Oncology ( Site 0091)

Recruiting

St. Petersburg, Florida, United States, 33709

Contacts

Study Coordinator

727-344-6569

Cleveland Clinic Martin North Hospital ( Site 0114)

Recruiting

Stuart, Florida, United States, 34994

Contacts

Study Coordinator

772-419-2146

Illinois Cancer Specialists (ICS) ( Site 8010)

Recruiting

Arlington Heights, Illinois, United States, 60005

Contacts

Study Coordinator

847-259-4482

Orchard Healthcare Research Inc. ( Site 0014)

Recruiting

Skokie, Illinois, United States, 60077

Contacts

Study Coordinator

224-534-7580

Northwest Cancer Center - Dyer Clinic ( Site 0097)

Recruiting

Dyer, Indiana, United States, 46311

Contacts

Study Coordinator

615-785-5914

Parkview Research Center at Parkview Regional Medical Center ( Site 0011)

Recruiting

Fort Wayne, Indiana, United States, 46845

Contacts

Study Coordinator

260-266-6313

Saint Elizabeth Medical Center Edgewood-Cancer Care Center ( Site 0044)

Recruiting

Edgewood, Kentucky, United States, 41017

Contacts

Study Coordinator

859-301-4000

CHRISTUS St. Frances Cabrini Hospital Center for Cancer Care ( Site 0109)

Recruiting

Alexandria, Louisiana, United States, 71301

Contacts

Study Coordinator

318-528-6976

Louisiana State University Health Sciences Shreveport ( Site 0029)

Recruiting

Shreveport, Louisiana, United States, 71103

Contacts

Study Coordinator

318-813-1429

Holy Cross Hospital ( Site 0069)

Recruiting

Silver Spring, Maryland, United States, 20910

Contacts

Study Coordinator

301-754-7552

University of Michigan ( Site 0103)

Recruiting

Ann Arbor, Michigan, United States, 48109

Contacts

Study Coordinator

800-865-1125

Henry Ford Health ( Site 0010)

Recruiting

Detroit, Michigan, United States, 48202

Contacts

Study Coordinator

313-598-2556

Metro-Minnesota Community Clinical Oncology ( Site 0031)

Recruiting

Saint Louis Park, Minnesota, United States, 55426

Contacts

Study Coordinator

952-993-3252

University of Mississippi Medical Center ( Site 0043)

Recruiting

Jackson, Mississippi, United States, 39216

Contacts

Study Coordinator

601-984-5590

Lake Regional Hospital ( Site 0009)

Recruiting

Osage Beach, Missouri, United States, 65065

Contacts

Study Coordinator

573-302-2772

Siteman Cancer Center ( Site 0099)

Recruiting

St Louis, Missouri, United States, 63108

Contacts

Study Coordinator

314-362-0263

Optum Care Cancer Center ( Site 9535)

Recruiting

Las Vegas, Nevada, United States, 89102

Contacts

Study Coordinator

702-724-8787

Comprehensive Cancer Centers of Nevada - Peak ( Site 0047)

Recruiting

Las Vegas, Nevada, United States, 89128

Contacts

Study Coordinator

702-609-9427

New Mexico Oncology Hematology Consultants Ltd. ( Site 0090)

Recruiting

Albuquerque, New Mexico, United States, 87109

Contacts

Study Coordinator

505-842-8171

CHRISTUS St. Vincent Regional Cancer Center ( Site 0118)

Recruiting

Santa Fe, New Mexico, United States, 87505

Contacts

Study Coordinator

505-913-8953

The Blavatnik Family- Chelsea Medical Center at Mount Sinai ( Site 0135)

Recruiting

New York, New York, United States, 10011

Contacts

Study Coordinator

212-604-6000

Icahn School of Medicine at Mount Sinai ( Site 0123)

Recruiting

New York, New York, United States, 10029

Contacts

Study Coordinator

212-241-3300

Memorial Sloan Kettering Cancer Center ( Site 0067)

Recruiting

New York, New York, United States, 10065

Contacts

Study Coordinator

212-639-2000

Clinical Research Alliance ( Site 0086)

Recruiting

Westbury, New York, United States, 11590

Contacts

Study Coordinator

516-734-8906

Levine Cancer Institute ( Site 0083)

Recruiting

Charlotte, North Carolina, United States, 28204

Contacts

Study Coordinator

980-442-3130

Cape Fear Valley Health System ( Site 0136)

Recruiting

Fayetteville, North Carolina, United States, 28304

Contacts

Study Coordinator

472-210-8847

Sanford Cancer Center Bismarck ( Site 0058)

Recruiting

Bismarck, North Dakota, United States, 58501

Contacts

Study Coordinator

701-323-5741

Sanford Fargo Medical Center-Roger Maris Cancer Center ( Site 0056)

Recruiting

Fargo, North Dakota, United States, 58102

Contacts

Study Coordinator

701-234-2000

Altru Cancer Center ( Site 0104)

Recruiting

Grand Forks, North Dakota, United States, 58201

Contacts

Study Coordinator

701-780-5451

Cleveland Clinic - Mercy Hospital ( Site 0057)

Recruiting

Canton, Ohio, United States, 44708

Contacts

Study Coordinator

330-489-1274

Tri-County Hematology & Oncology Associates, Inc. ( Site 0076)

Recruiting

Massillon, Ohio, United States, 44646

Contacts

Study Coordinator

330-478-0001

Taylor Cancer Research Center ( Site 9500)

Recruiting

Maumee, Ohio, United States, 43537

Contacts

Study Coordinator

567-402-4501

Genesis Healthcare System ( Site 0025)

Recruiting

Zanesville, Ohio, United States, 43701

Contacts

Study Coordinator

740-454-5271

Oklahoma Cancer Specialists and Research Institute, LLC ( Site 0041)

Recruiting

Tulsa, Oklahoma, United States, 74146

Contacts

Study Coordinator

918-505-3200

Providence Portland Medical Center ( Site 0116)

Recruiting

Portland, Oregon, United States, 97213

Contacts

Study Coordinator

503-215-1979

Providence Oncology and Hematology Care Clinic - Westside ( Site 0126)

Recruiting

Portland, Oregon, United States, 97225

Contacts

Study Coordinator

503-215-1979

Sidney Kimmel Cancer Center at Jefferson ( Site 0049)

Recruiting

Philadelphia, Pennsylvania, United States, 19107

Contacts

Study Coordinator

215-955-8874

Cancer Care Associates Of York ( Site 9517)

Recruiting

York, Pennsylvania, United States, 17403

Contacts

Study Coordinator

717-741-9229

Sanford Cancer Center ( Site 0059)

Recruiting

Sioux Falls, South Dakota, United States, 57104

Contacts

Study Coordinator

605-328-8000

West Cancer Center and Research Institute ( Site 0084)

Recruiting

Germantown, Tennessee, United States, 38138

Contacts

Study Coordinator

901-683-0055

Baptist Cancer Center ( Site 0101)

Recruiting

Memphis, Tennessee, United States, 38120

Contacts

Study Coordinator

901-226-3077

One Oncology - Tennessee Oncology ( Site 0098)

Recruiting

Nashville, Tennessee, United States, 37203

Contacts

Study Coordinator

615-986-4350

SCRI Oncology Partners ( Site 7000)

Recruiting

Nashville, Tennessee, United States, 37203

Contacts

Study Coordinator

615-329-7274

Tennessee Oncology ( Site 0111)

Recruiting

Nashville, Tennessee, United States, 37203

Contacts

Study Coordinator

615-986-4350

Vanderbilt Health One Hundred Oaks ( Site 0042)

Recruiting

Nashville, Tennessee, United States, 37212

Contacts

Study Coordinator

800-811-8480

Hendrick Medical Center ( Site 0117)

Recruiting

Abilene, Texas, United States, 79601

Contacts

Study Coordinator

325-670-2000

Harrington Cancer Center ( Site 0061)

Recruiting

Amarillo, Texas, United States, 79106

Contacts

Study Coordinator

806-359-4673

Texas Oncology - DFW ( Site 8000)

Recruiting

Dallas, Texas, United States, 75246

Contacts

Study Coordinator

214-370-1000

Parkland Health & Hospital System ( Site 0096)

Recruiting

Dallas, Texas, United States, 75390

Contacts

Study Coordinator

214-645-4673

University of Texas Southwestern Medical Center ( Site 0032)

Recruiting

Dallas, Texas, United States, 75390

Contacts

Study Coordinator

214-645-4673

Texas Oncology - Northeast Texas ( Site 8005)

Recruiting

Flower Mound, Texas, United States, 75028

Contacts

Study Coordinator

972-537-4100

John Peter Smith Hospital ( Site 0106)

Recruiting

Fort Worth, Texas, United States, 76104

Contacts

Study Coordinator

817-702-8049

Oncology Consultants P.A. ( Site 0107)

Recruiting

Houston, Texas, United States, 77030

Contacts

Study Coordinator

713-600-0900

Laguna Clinical Research Associates LLC ( Site 0068)

Recruiting

Laredo, Texas, United States, 78041

Contacts

Study Coordinator

956-724-8543

Mays Cancer Center ( Site 0122)

Recruiting

San Antonio, Texas, United States, 78229

Contacts

Study Coordinator

210-450-1000

The University of Texas Health Science Center at Tyler dba UT Health East Texas HOPE Cancer Center ( Site 0055)

Recruiting

Tyler, Texas, United States, 75701

Contacts

Study Coordinator

903-592-6152

Texas Oncology - Gulf Coast ( Site 8009)

Recruiting

Webster, Texas, United States, 77598

Contacts

Study Coordinator

281-332-7505

Intermountain Medical Center ( Site 0113)

Recruiting

Murray, Utah, United States, 84107

Contacts

Study Coordinator

801-507-3630

Mary Washington Hospital ( Site 0129)

Recruiting

Fredericksburg, Virginia, United States, 22405

Contacts

Study Coordinator

540-300-6182

Hematology Oncology Associates of Fredericksburg ( Site 9550)

Recruiting

Fredericksburg, Virginia, United States, 22408

Contacts

Study Coordinator

540-371-0079

Bon Secours Memorial Regional Medical Center-Oncology Research Department ( Site 0020)

Recruiting

Midlothian, Virginia, United States, 23114

Contacts

Study Coordinator

804-893-8717

Virginia Oncology Associates (VOA) ( Site 8008)

Recruiting

Norfolk, Virginia, United States, 23502

Contacts

Study Coordinator

646-694-8125

Virginia Cancer Institute ( Site 0034)

Recruiting

Richmond, Virginia, United States, 23229

Contacts

Study Coordinator

804-287-3000

Northwest Medical Specialties, PLLC ( Site 0093)

Recruiting

Tacoma, Washington, United States, 98405

Contacts

Study Coordinator

253-428-8700

SSM Health Dean Medical Group ( Site 0087)

Recruiting

Madison, Wisconsin, United States, 53715

Contacts

Study Coordinator

516-488-2918

Cross Cancer Institute ( Site 0407)

Recruiting

Edmonton, Alberta, Canada, T6G 1Z2

Contacts

Study Coordinator

7804328956

BC Cancer Vancouver ( Site 0404)

Recruiting

Vancouver, British Columbia, Canada, V5Z 4E6

Contacts

Study Coordinator

6048776000

CancerCare Manitoba ( Site 0411)

Recruiting

Winnipeg, Manitoba, Canada, R2H 2A6

Contacts

Study Coordinator

2047872127

The Moncton Hospital ( Site 0401)

Recruiting

Moncton, New Brunswick, Canada, E1C 6Z8

Contacts

Study Coordinator

5068575756

QEII Health Sciences Centre - Victoria General Site ( Site 0418)

Recruiting

Halifax, Nova Scotia, Canada, B3H 2Y9

Contacts

Study Coordinator

9024732160

Kingston Health Sciences Centre-Kingston General Hospital Site ( Site 0422)

Recruiting

Kingston, Ontario, Canada, K7L 2V7

Contacts

Study Coordinator

613-549-6666

Southlake Health ( Site 0413)

Recruiting

Newmarket, Ontario, Canada, L3Y 2P9

Contacts

Study Coordinator

9058954521x5155

The Ottawa Hospital - General Campus ( Site 0414)

Recruiting

Ottawa, Ontario, Canada, K1H 8L6

Contacts

Study Coordinator

6137377700x70208

North York General Hospital ( Site 0415)

Recruiting

Toronto, Ontario, Canada, M2K 1E1

Contacts

Study Coordinator

4167566000

Princess Margaret Cancer Centre ( Site 0400)

Recruiting

Toronto, Ontario, Canada, M5G 2M9

Contacts

Study Coordinator

4169464501x2245

Centre Intégré de Santé et de Services Sociaux de la Montérégie-Centre ( Site 0417)

Recruiting

Greenfield Park, Quebec, Canada, J4V 2H1

Contacts

Study Coordinator

4504665000x3226

CIUSSS de l'Est-de-l'Île-de-Montréal ( Site 0419)

Recruiting

Montreal, Quebec, Canada, H1T 2M4

Contacts

Study Coordinator

5142523400x6244

Centre Hospitalier de l'Université de Montréal ( Site 0403)

Recruiting

Montreal, Quebec, Canada, H2X 3E4

Contacts

Study Coordinator

5148908000

Jewish General Hospital ( Site 0416)

Recruiting

Montreal, Quebec, Canada, H3T 1E2

Contacts

Study Coordinator

5143405222x27562

Centre intégré de santé et de services sociaux du Bas Saint-Laurent- Hôpital régional de Rimouski ( Site 0409)

Recruiting

Rimouski, Quebec, Canada, G5L 5T1

Contacts

Study Coordinator

4187243000x8029

Centre integre universitaire de sante et de services sociaux de la Mauricie-et-du-centre-du-quebec ( Site 0406)

Recruiting

Trois-Rivières, Quebec, Canada, G8Z 3R9

Contacts

Study Coordinator

8196973333x63238

More Information

Sponsor

Merck Sharp & Dohme LLC

Last update posted

Sep 3, 2026

Last verified

Sep, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-08. This information was provided to ClinicalTrials.gov by Merck Sharp & Dohme LLC on 2026-09-03.